← Leaderboards
Gary L Olson
Provid Pharmaceuticals, Inc
$571,968
Attributed
$684,448
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $225K · FY2005–14$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$684,448 · 4
By mechanism
R43$684,448 · 4
Top collaborators
- Wafik S El-Deiry1 shared
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeAnalogBiologicalAnimal ModelPropertyPharmacologic SubstanceLeadPharmaceutical PreparationsMimeticsPathway InteractionsInnovationMultiple SclerosisPeptide AnalogPeptidesBinding SitesIn VitroBinding (Molecular Function)BaseDoseChemistryInhibitor /AntagonistInhibitor/AntagonistCell ModelDesign
Grant awards (5)
TRAIL Upregulation by TIC10 Analogs$224,960
R43 · FY2014 · CA · contact PI
F11R antagonists for atherosclerosis$175,200
R43 · FY2010 · HL · contact PI
MHC Class II inhibitors for Multiple Sclerosis$67,410
R43 · FY2007 · NS · contact PI
Design and Assay of DQ2 Inhibitors for Celiac Disease$106,881
R43 · FY2005 · DK
MHC Class II inhibitors for Multiple Sclerosis$109,997
R43 · FY2004 · NS